CA2206119A1 - Irrigation solution and method for inhibition of pain, inflammation and spasm - Google Patents

Irrigation solution and method for inhibition of pain, inflammation and spasm

Info

Publication number
CA2206119A1
CA2206119A1 CA002206119A CA2206119A CA2206119A1 CA 2206119 A1 CA2206119 A1 CA 2206119A1 CA 002206119 A CA002206119 A CA 002206119A CA 2206119 A CA2206119 A CA 2206119A CA 2206119 A1 CA2206119 A1 CA 2206119A1
Authority
CA
Canada
Prior art keywords
antagonists
receptor
receptor antagonists
solution
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002206119A
Other languages
French (fr)
Other versions
CA2206119C (en
Inventor
Gregory A. Demopulos
Pamela Anne Pierce
Jeffrey M. Herz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems, Inc.
Gregory A. Demopulos
Pamela Anne Pierce
Jeffrey M. Herz
Omeros Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems, Inc., Gregory A. Demopulos, Pamela Anne Pierce, Jeffrey M. Herz, Omeros Corporation filed Critical Omeros Medical Systems, Inc.
Publication of CA2206119A1 publication Critical patent/CA2206119A1/en
Application granted granted Critical
Publication of CA2206119C publication Critical patent/CA2206119C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis

Abstract

A method and solution for perioperatively inhibiting a variety of pain and inflammation and spasm processes at a wound. The solution includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic base, such as saline or lactated Ringer's solution. Depending on the application, the pain and inflammation agents included in the solution may include:
(1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin1 and neurokinin2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachadonic acid metabolites, including (a) phospholipase inhibitors, including PLA2 isoform and PLC .gamma. isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipooxygenase inhibitors; (10) prostanoid receptor antagonists including eicosanoid EP-1 and EP-2 receptor subtype antagonists and thromboxane receptor subtype antagonists;
(11) leukotriene receptor antagonists including leukotriene B4 and D4 receptor subtype antagonists; (12) opioid receptor agonists, including mu-opiate, delta-opiate, and kappa-opiate receptor sybtype agonists; (13) purinoceptor agonists and antagonists including P2X receptor antagonists and P2Y receptor agonists; (14) adenosine triphosphate (ATP)-sensitive potassium channel openers; and (15) calcium channel antagonists. Suitable anti-inflammatory/anti-pain agents which also act as anti-spasm agents include serotonin receptor antagonists, tachykinin receptor antagonists, ATP-sensitive potassium channel openers and calcium channel antagonists. Other agents which may be utilized in the solution specifically for their anti-spasm properties including endothelin receptor antagonists and the nitric oxyde donors (enzyme activators). The solution is used to continuously irrigate a wound during an operative/interventional procedure for preemptive inhibition of pain and inflammation, as well as vascular and smooth muscle spasm, while avoiding undesirable side effects associated with oral, intramuscular or intravenous application of larger doses of the agents.
The solution is useful for arthroscopic, intravascular and urologic procedures, as well as for application to burns, and intra- and postoperative application to surgical wounds.
CA002206119A 1994-12-12 1995-12-12 Irrigation solution and method for inhibition of pain, inflammation and spasm Expired - Lifetime CA2206119C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35377594A 1994-12-12 1994-12-12
US08/353,775 1994-12-12
PCT/US1995/016028 WO1996019233A2 (en) 1994-12-12 1995-12-12 Irrigation solution and method for inhibition of pain, inflammation and spasm

Publications (2)

Publication Number Publication Date
CA2206119A1 true CA2206119A1 (en) 1996-06-27
CA2206119C CA2206119C (en) 2008-05-13

Family

ID=23390519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002206119A Expired - Lifetime CA2206119C (en) 1994-12-12 1995-12-12 Irrigation solution and method for inhibition of pain, inflammation and spasm

Country Status (13)

Country Link
US (6) US5800385A (en)
EP (3) EP2301562B1 (en)
JP (3) JP2007031454A (en)
CN (1) CN1160115C (en)
AT (2) ATE300308T1 (en)
CA (1) CA2206119C (en)
DE (1) DE69534341T2 (en)
ES (3) ES2244966T3 (en)
HK (1) HK1008983A1 (en)
MX (1) MX9703988A (en)
NO (1) NO20055445L (en)
RU (1) RU2180852C2 (en)
WO (1) WO1996019233A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790696B2 (en) 2005-05-20 2014-07-29 Omeros Corporation Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087479A (en) * 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
KR100517210B1 (en) * 1994-12-12 2006-06-07 오메로스 코포레이션 Infusion solution for pain, inflammation and spasm
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO2000023066A2 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR9509985A (en) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solution for irrigation and method for inhibiting pain, inflammation and sparse
KR100499190B1 (en) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 Hair restorer
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CN1187050C (en) 1997-09-26 2005-02-02 克诺尔有限公司 Endothelin antogonist and a renin-angiotensin system inhibitor as a combined preparation
DE19743142A1 (en) * 1997-09-30 1999-04-01 Knoll Ag Combination pharmaceutical preparations
DE19743143A1 (en) * 1997-09-30 1999-04-01 Knoll Ag Combination pharmaceutical preparations
UA53774C2 (en) 1997-12-22 2003-02-17 Еро-Селтік, С.А. Method of reducing abuse potential of an oral dosage form of opioid analgesic
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JPH11217330A (en) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd Neurotrophic factor secretagogue
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
EP1067950B1 (en) * 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
CA2346228A1 (en) * 1998-10-09 2000-04-20 Schering Corporation Composition and method for treating allergic diseases
EP1563838A3 (en) * 1998-10-20 2009-11-04 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
EP1044012B1 (en) * 1998-11-10 2006-05-03 Temple University of the Commonwealth System of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
AU3422800A (en) 1999-02-18 2000-09-04 Novartis Ag Use of 5-ht3 receptor antagonists
ATE306489T1 (en) 1999-03-08 2005-10-15 Medicure Inc PYRIDOXAL ANALOGUE FOR THE TREATMENT OF DISORDERS CAUSED BY VITAMIN B6 DEFICIENCY
US7091140B1 (en) 1999-04-07 2006-08-15 Polymer Group, Inc. Hydroentanglement of continuous polymer filaments
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6139535A (en) * 1999-05-27 2000-10-31 Situs Corporation Method and apparatus for placement and activation of a medical device within a body cavity
WO2001003682A2 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
EP1210117A2 (en) * 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6994852B1 (en) * 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
CA2396739A1 (en) 1999-12-06 2001-06-14 Krishna G. Peri Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
SI2517710T1 (en) 2000-02-08 2015-07-31 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6605612B2 (en) 2000-02-29 2003-08-12 Medicure International Inc. Cardioprotective phosohonates and malonates
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
NZ523815A (en) 2000-07-07 2004-07-30 Medicure Int Inc Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
EA005649B1 (en) 2000-08-11 2005-04-28 Дэвид Р. Уитлок Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US6902564B2 (en) * 2001-08-15 2005-06-07 Roy E. Morgan Methods and devices for electrosurgery
US7771422B2 (en) 2002-06-06 2010-08-10 Nuortho Surgical, Inc. Methods and devices for electrosurgery
US7445619B2 (en) * 2000-08-18 2008-11-04 Map Technologies Llc Devices for electrosurgery
US7819861B2 (en) * 2001-05-26 2010-10-26 Nuortho Surgical, Inc. Methods for electrosurgical electrolysis
JP2004524270A (en) * 2000-09-26 2004-08-12 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド Tricyclic antidepressants and their analogs as long-acting anesthetics and analgesics
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
CA2443050A1 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
JP4522652B2 (en) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド Abuse prevention controlled release opioid dosage form
US7066932B1 (en) 2001-05-26 2006-06-27 Map Technologies Llc Biologically enhanced irrigants
ITMI20011308A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR CHRONIC PAIN
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
MXPA04001210A (en) 2001-08-06 2004-07-08 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US8734441B2 (en) 2001-08-15 2014-05-27 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
US8591508B2 (en) * 2001-08-15 2013-11-26 Nuortho Surgical, Inc. Electrosurgical plenum
US8235979B2 (en) 2001-08-15 2012-08-07 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
EP1434610A4 (en) 2001-10-12 2008-07-30 Applied Med Resources High-flow low-pressure irrigation system
EP1448152A4 (en) * 2001-10-31 2006-06-07 Millennium Pharm Inc Methods and compositions for the treatment and diagnosis of pain disorders using 2047
JP4317452B2 (en) 2001-11-01 2009-08-19 スペクトラム・ファーマシューティカルス・インコーポレーテッド Medical composition for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
WO2003057380A2 (en) * 2002-01-11 2003-07-17 Whitlock David R Compositions including ammonia oxidizing bacteria and methods of using same
AU2003211009A1 (en) * 2002-02-11 2003-09-04 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
JP4620355B2 (en) 2002-04-05 2011-01-26 ユーロ−セルティーク エス．エイ． Matrix for sustained, constant and independent release of active compounds
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1531791E (en) * 2002-06-07 2010-12-16 Dyax Corp Prevention and reduction of ischemia
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CN1684701B (en) 2002-07-30 2012-10-17 奥默罗斯公司 Ophthalmologic irrigation solutions and method
WO2004019968A1 (en) * 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
CN1703200B (en) 2002-09-20 2012-02-29 奥尔制药公司 Sequestering subunit and related compositions and methods
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CA2524883C (en) 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
WO2005030147A2 (en) * 2003-09-26 2005-04-07 Whitlock David R Methods of using ammonia oxidizing bacteria
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007534361A (en) * 2003-12-15 2007-11-29 ニトリカーレ・ハンデルスボラーグ Device and method for administering therapeutic agents
BRPI0509993A (en) * 2004-04-20 2007-10-16 Pfizer Prod Inc combinations comprising alpha-2-delta ligands
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CN101014357A (en) * 2004-07-07 2007-08-08 麦迪库瑞国际公司 Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7812037B2 (en) * 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
CA2632090A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
WO2007100718A2 (en) * 2006-02-24 2007-09-07 Denise Barbut Neurotensin receptor agonists and opioid receptor agonists
EP2001500A4 (en) * 2006-03-10 2010-07-28 Dyax Corp Formulations for ecallantide
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2719378T3 (en) 2006-06-19 2016-10-17 Alpharma Pharmaceuticals Llc pharmaceutical compositions
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
RU2009111605A (en) 2006-08-31 2010-10-10 Спектрум Фармасьютикалз, Инк. (Us) SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY BY INTRODUCING ENDOTHELINE AGONISTS
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (en) * 2006-11-28 2009-11-11 威朗国际制药公司 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
PE20110422A1 (en) * 2008-07-07 2011-07-01 Euro Celtique Sa PHARMACEUTICAL COMPOSITION INCLUDING OPIOID ANTAGONISTS
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
PT2405915T (en) 2009-03-10 2019-01-29 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9532827B2 (en) 2009-06-17 2017-01-03 Nuortho Surgical Inc. Connection of a bipolar electrosurgical hand piece to a monopolar output of an electrosurgical generator
ES2688093T3 (en) * 2010-01-06 2018-10-30 Dyax Corp. Plasma kallikrein binding proteins
RS54889B1 (en) * 2010-12-09 2016-10-31 Radikal Therapeutics Inc Multifunctional nitroxide derivatives and uses thereof
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US9408658B2 (en) 2011-02-24 2016-08-09 Nuortho Surgical, Inc. System and method for a physiochemical scalpel to eliminate biologic tissue over-resection and induce tissue healing
KR101951064B1 (en) * 2011-08-04 2019-02-21 오메로스 코포레이션 Stable anti-inflammatory solutions for injection
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9579142B1 (en) 2012-12-13 2017-02-28 Nuortho Surgical Inc. Multi-function RF-probe with dual electrode positioning
US11559521B2 (en) 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR101462474B1 (en) * 2013-10-30 2014-11-19 주식회사 큐리언트 Topical anti-inflammatory pharmaceutical formulation of cream formulation comprising zileuton
BR112016022318A2 (en) 2014-03-27 2017-10-31 Dyax Corp method, pharmaceutical composition for use in the treatment of retinal diseases and use of an antibody
US20170037363A1 (en) 2014-04-15 2017-02-09 Aobiome Llc Ammonia-oxidizing nitrosomonas eutropha strain d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
CN105031381A (en) * 2015-09-08 2015-11-11 济南舜昊生物科技有限公司 Drug for oral local anesthesia of pregnant woman and preparation method thereof
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
SG11201912036XA (en) * 2017-07-06 2020-01-30 Caventure Drug Discovery Inc A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
CN110123833A (en) * 2019-05-31 2019-08-16 龚啸元 A kind of arthrocsopic surgery perfusate and preparation method thereof
CN111000983A (en) * 2019-12-25 2020-04-14 长春生物制品研究所有限责任公司 Medicinal use of new recombinant human interleukin-1 receptor antagonist

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
DE3316510A1 (en) * 1983-05-06 1984-11-08 Bayer Ag PARENTERAL FORMULATION OF NIMODIPIN, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN THE FIGHT AGAINST DISEASES
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
US4504493A (en) 1983-07-15 1985-03-12 University Of Southern California By G. June Marshall Solution for surgical irrigation
SU1337105A1 (en) * 1985-05-07 1987-09-15 Киевский Научно-Исследовательский Институт Медицинских Проблем Физической Культуры Method of treatment of burns
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US4872865A (en) * 1985-10-09 1989-10-10 Harrington Arthritis Research Center Hypertonic solution for arthroscopic surgery
FR2598081B1 (en) * 1986-04-30 1990-02-02 Chauvin Blache Lab PROCESS FOR THE PREPARATION OF AN AQUEOUS PHARMACEUTICAL SOLUTION OF AN ACTIVE INGREDIENT CONSTITUTED BY AN ORGANIC ACID
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5272139A (en) * 1986-08-27 1993-12-21 Cary George R Jr Amelioration or elimination of postoperative pain
JPS63115818A (en) * 1986-08-27 1988-05-20 ジヨ−ジ・ア−ル・ケイリ−・ジュニア Local composition for improving or extinguishing pain after operation
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
JPH01135721A (en) * 1987-10-29 1989-05-29 Geneco Inc Method and solution for removing intraperitoneal infection
CA1341093C (en) * 1988-05-31 2000-09-05 Eugene P. Goldberg Method and composition for preventing surgical adhesions
USH1139H (en) * 1988-07-21 1993-02-02 E. R. Squibb & Sons, Inc. Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
US5304724A (en) * 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5051443A (en) * 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5036046A (en) * 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
JPH05506035A (en) * 1990-09-07 1993-09-02 ユニベルシダド、ド、アリカンテ Composition for treating eye pain
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
DE69107309T2 (en) * 1990-12-03 1995-06-08 Vestar Inc PREVENTION OF SYNOVIAL ADHESION.
JP2520895Y2 (en) * 1990-12-28 1996-12-18 曙ブレーキ工業株式会社 Disc brake pressure oil introduction section
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
ATE202708T1 (en) * 1991-04-19 2001-07-15 Scios Nova Inc PEPTIDE ANTAGONISTS OF BRADYKININ
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
ATE195867T1 (en) * 1991-09-20 2000-09-15 Glaxo Group Ltd NEW MEDICAL INDICATION FOR TACHYKININ ANTAGONISTS
DE4135157C2 (en) * 1991-10-24 1995-06-14 Luitpold Pharma Gmbh Use of aqueous carbohydrate solutions as rinsing liquid for arthroscopy
GB9216155D0 (en) * 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
US5650447A (en) * 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5525357A (en) * 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5521158A (en) * 1992-10-08 1996-05-28 Scios Nova Inc. Pseudopeptide bradykinin receptor antagonists
AU5405894A (en) * 1992-10-21 1994-05-09 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
JPH09506620A (en) * 1993-12-17 1997-06-30 アルコン・ラボラトリーズ，インコーポレイテッド Improved intraocular irrigation solution containing non-steroidal anti-inflammatory agents
US5482925A (en) * 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
BR9509985A (en) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solution for irrigation and method for inhibiting pain, inflammation and sparse
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2004031143A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7358091B2 (en) * 2004-12-14 2008-04-15 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790696B2 (en) 2005-05-20 2014-07-29 Omeros Corporation Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
US9855256B2 (en) 2005-05-20 2018-01-02 Omeros Corporation Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures

Also Published As

Publication number Publication date
EP1609477A1 (en) 2005-12-28
MX9703988A (en) 1998-02-28
EP0799051A2 (en) 1997-10-08
HK1008983A1 (en) 1999-07-23
JP2007031454A (en) 2007-02-08
CN1175213A (en) 1998-03-04
WO1996019233A2 (en) 1996-06-27
EP2301562B1 (en) 2013-04-17
US20080167388A1 (en) 2008-07-10
RU2180852C2 (en) 2002-03-27
US5858017A (en) 1999-01-12
ES2244966T3 (en) 2005-12-16
WO1996019233A3 (en) 1996-09-19
ES2377126T3 (en) 2012-03-22
ATE532530T1 (en) 2011-11-15
EP0799051B1 (en) 2005-07-27
JP2012184274A (en) 2012-09-27
ATE300308T1 (en) 2005-08-15
CA2206119C (en) 2008-05-13
JP2009024022A (en) 2009-02-05
DE69534341T2 (en) 2006-05-24
US20080096948A1 (en) 2008-04-24
US5860950A (en) 1999-01-19
DE69534341D1 (en) 2005-09-01
EP1609477B1 (en) 2011-11-09
US5800385A (en) 1998-09-01
ES2421306T3 (en) 2013-08-30
EP2301562A1 (en) 2011-03-30
US20080114025A1 (en) 2008-05-15
NO20055445L (en) 1997-08-07
CN1160115C (en) 2004-08-04

Similar Documents

Publication Publication Date Title
CA2206119A1 (en) Irrigation solution and method for inhibition of pain, inflammation and spasm
WO2001007067A3 (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation
AU6397496A (en) Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
RU94045285A (en) Composition against acne at simultaneous treatment of surface and deep skin layer and its use
DK1615647T3 (en) Pharmaceutical use of condensed 1,2,4-triazoles
RU97112158A (en) INHIBITING SOLUTION AND METHOD FOR SUPPRESSING PAIN, INFLAMMATION OR SPASMA
ES2139740T3 (en) TWO-COMPONENT FIBRINE GLUE.
BR9914158A (en) Antibiotic composition for the treatment of eyes, ears and nose
Rodeheaver et al. Proteolytic enzymes as adjuncts to antimicrobial prophylaxis of contaminated wounds
WO2000023062A3 (en) Irrigation solution and method for inhibition of pain and inflammation
WO2000023066A3 (en) Irrigation solution and method for inhibition of pain and inflammation
AU1345000A (en) Irrigation solution and method for inhibition of pain and inflammation
ES2193185T3 (en) PHARMACEUTICAL FORMULATION FOR THE PREVENTION OR PRIOR TREATMENT OF AN INTOXICATION WITH INHIBITORS OF THE ORGANOPHOSPHORATED CHOLINESTERASE.
Callas et al. The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial
GB9930768D0 (en) Composition
WO2000023061A3 (en) Irrigation solution and method for inhibition of pain and inflammation
BR9916733A (en) Arylalkanine derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
Colman et al. High molecular weight kininogen, the extracellular inhibitor of thiol proteases, is deficient in hamsters with muscular dystrophy
WO2003049723A3 (en) Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
EP1563838A3 (en) Irrigation solution and method for inhibition of pain and inflammation
Jackson et al. Immunolocalisation of two angiogenic factors (PDECGF and VEGF) in human placental villi throughout gestation
Walsh ADVANCES IN HEMATOLOGY
Lipopolysaccharide-Stimulated Suppresses 2 Prostaglandin E
RU95108306A (en) Agent for chronic pyelonephrosis treatment
MX9709983A (en) Use of angiotensin ii type 2 receptor agonists in tissue repair.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151214